iCo Therapeutics Welcomes Dr. Jason Slakter to Strategic Advisory Board

    VANCOUVER, June 28 /PRNewswire/ - iCo Therapeutics Inc. announced today
 that Dr. Jason Slakter will join its strategic advisory team. An
 internationally renowned retinal specialist, Dr. Slakter currently
 practices at the Vitreous-Retina-Macula Consultants in New York. He is a
 Clinical Professor of Ophthalmology at the New York University School of
 Medicine and an attending surgeon and Surgeon Director at the Manhattan
 Eye, Ear and Throat Hospital.
     "We are pleased to have Dr. Slakter join our advisory team," said
 Andrew Rae, iCoTherapeutics' President and Chief Executive Officer. "His
 clinical experience and expertise in the development and application of a
 variety of diagnostic techniques adds impressive bench strength to our
 team."
     Dr. Slakter's expertise in macular disease diagnostics is extensive. He
 has played a leading role and is widely published in the development of
 digital indocyanine green angiography (ICG) for the evaluation and
 management of macular degeneration and chorioretinal inflammatory disease.
 He created and is the director of the Digital Angiography Reading Center,
 which serves as a key resource for numerous industry-sponsored studies. He
 has served as a Principal Investigator in the clinical trials for
 photodynamic therapy for the treatment of wet AMD and is currently
 conducting clinical studies for the treatment of central serous
 chorioretinopathy.
     Dr. Slakter is a member of numerous medical organizations including the
 Macula and Retina Societies, and the American Society of Retinal
 Specialists. He is the Editor-in-Chief of Retinal Physician, is on the
 editorial board of Retina and serves as a scientific reviewer for major
 scientific ophthalmic journals. He is the recipient of a number of awards
 including the American Academy of Ophthalmology Honor Award, the Macula
 Society's Richard and Hinda Rosenthal Award, and the Helen Keller Manhattan
 League Award.
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new
 conditions affecting isolated biological environments-areas such as the
 eye, spinal cord, or joints-where locally-administered application of these
 therapies would have minimal systemic distribution and fewer safety issues.
     For more information, visit the company website at:
 www.icotherapeutics.com
     Business Development Contact:              Finance, Investor Contact:
     Dr. John Clement, CT&DO                    Mr. John Meekison, CFO
     778.688.0644                               604.602.9414
 
     Media Contact:
     Amanda Smith, Principal, Smith Biotech
     778-846-4116
 
 

SOURCE iCo Therapeutics Inc.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.